Journal of gastrointestinal oncology最新文献

{"title":"Training and validation of a nomogram for predicting synchronous distant organ metastasis in patients with very-early-onset colorectal cancer.","authors":"Yajing Wen, Zhemin Li, Huilian Zhang, Jinyu Huang, Yuqin Zhang, Yi Ding, Jianbiao Xiao, Yaowei Zhang","doi":"10.21037/jgo-2025-733","DOIUrl":"https://doi.org/10.21037/jgo-2025-733","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) ranks among the leading causes of cancer-related mortality, with a sharp rise in incidence among patients diagnosed before age 40, a group classified as having very-early-onset CRC (VEO-CRC). Because synchronous distant organ metastasis (DOM) at diagnosis is common and worsens survival, this study aimed to identify predictors of DOM, develop and internally validate a nomogram to estimate individual DOM risk, and evaluate its potential clinical utility.</p><p><strong>Methods: </strong>Utilizing data from the Surveillance, Epidemiology, and End Results (SEER) database spanning 2010 to 2020, we identified patients diagnosed with malignant colorectal adenocarcinoma under 40 years. Patients who met the inclusion criteria were randomly assigned to the training set and the validation set. Logistic regression analyses were performed to identify risk factors for DOM, which were subsequently used to construct a nomogram. The model's performance was assessed through receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA).</p><p><strong>Results: </strong>A total of 8,097 VEO-CRC patients were assigned to training (n=5,667) and validation (n=2,430) cohorts. DOM among patients with malignant colorectal adenocarcinoma under 40 years was 23.04%. Multivariate analysis revealed seven independent risk factors for DOM: race, tumor size, primary tumor location, histopathological grade, tumor (T) stage, node (N) stage, and carcinoembryonic antigen (CEA) level. The nomogram demonstrated an area under the curve (AUC) of 0.846 [95% confidence interval (CI): 0.834-0.858] for the training cohort and 0.833 (95% CI: 0.813-0.852) for the validation cohort, indicating strong predictive accuracy. The clinical utility of the nomogram was verified in the DCA.</p><p><strong>Conclusions: </strong>The predictive nomogram, derived from demographic, clinical, and pathological data from the SEER database, provides an estimation of the DOM risk in VEO-CRC patients. This is a promising tool to improve outcomes for young patients by assisting physicians in early risk stratification and bespoke treatment planning. At prespecified risk thresholds, the predicted probabilities may assist early risk stratification and inform imaging and follow-up decisions, though their clinical application will require confirmation through rigorous external validation.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 1","pages":"6"},"PeriodicalIF":2.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147433322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>FTSJ1</i>-mediated <i>IL1RN</i> mRNA instability promotes inflammation-driven hepatocellular carcinoma.","authors":"Shuya Jiang, Dongyang Ding, Yunxi Zu, Yan Liao, Tengjiao Wang, Jian Yu, Weiping Zhou, Shengxian Yuan","doi":"10.21037/jgo-2025-693","DOIUrl":"https://doi.org/10.21037/jgo-2025-693","url":null,"abstract":"<p><strong>Background: </strong>The role of 2'-O-methyltransferases in hepatocellular carcinoma (HCC) progression, particularly concerning inflammation, remains unclear. This study investigated their prognostic significance, identified key prognostic target <i>FTSJ1</i>, and elucidated its inflammatory-related biological functions and molecular mechanisms.</p><p><strong>Methods: </strong>Transcriptomic data from The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA-LIHC) were integrated to data of subtype HCC patients via consensus clustering based on 2'-O-methyltransferase expression. Single-gene survival analysis linked <i>FTSJ1</i>, <i>FTSJ2</i>, <i>FTSJ3</i>, and <i>FBL</i> to prognosis. A four-gene risk model was built. Multivariate COX regression identified independent risk factors. <i>FTSJ1</i> expression and prognostic value were validated clinically using quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). Functional roles were assessed <i>in vitro</i> [Cell Counting Kit-8 (CCK-8), Transwell, apoptosis/cell cycle assays] and <i>in vivo</i> (xenograft models). Mechanisms were explored via RNA sequencing (RNA-seq), gene set enrichment analysis (GSEA), and inflammatory cytokine detection.</p><p><strong>Results: </strong>Consensus clustering defined three subtypes. Subtype 1 (high 2'-O-methyltransferase expression) showed the worst prognosis. <i>FTSJ1/2/3</i> and <i>FBL</i> correlated significantly with survival. The four-gene risk model predicted survival across cohorts [The Cancer Genome Atlas (TCGA)/Gene Expression Omnibus (GEO) datasets (GSE54236/GSE144269)]. <i>FTSJ1</i> was an independent risk factor [multivariate Cox, hazard ratio (HR) =2.268, P=0.01] and significantly elevated in HCC tissues. Functionally, <i>FTSJ1</i> knockdown inhibited proliferation and migration; induced G0/G1 arrest; promoted apoptosis <i>in vitro</i>; and suppressed tumor growth <i>in vivo</i>. Mechanistically, <i>FTSJ1</i> drove HCC progression by reducing RNA stability of the key anti-inflammatory gene interleukin 1 receptor antagonist (<i>IL1RN</i>), leading to downregulated tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) and enhanced pro-inflammatory signaling.</p><p><strong>Conclusions: </strong>High 2'-O-methyltransferase abundance predicts poor HCC prognosis. <i>FTSJ1</i> is a novel independent prognostic biomarker and oncogenic factor that promotes HCC progression by dysregulating the inflammatory response pathway, highlighting its translational potential in inflammation-driven HCC.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 1","pages":"26"},"PeriodicalIF":2.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147432516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CPNE3 promotes colorectal cancer progression by regulating KIF4-mediated autophagy.","authors":"Chong Tang, Wu Teng, Yasu Jiang, Yongyou Wu","doi":"10.21037/jgo-2025-735","DOIUrl":"https://doi.org/10.21037/jgo-2025-735","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide. This study examines the role of CPNE3 in CRC progression and its interaction with KIF4 to identify potential therapeutic targets.</p><p><strong>Methods: </strong>We identified CPNE3 as a candidate oncogene using bioinformatics. Its expression was measured by quantitative real-time polymerase chain reaction (qRT-PCR) in CRC tissues and cell lines. The effects of CPNE3 on proliferation, colony formation, migration, invasion, apoptosis, and autophagy were tested with gain- and loss-of-function experiments. Co-immunoprecipitation (IP), immunofluorescence, and Biological General Repository for Interaction Datasets (BIOGRID) analysis were used to find interacting proteins and pathways. KIF4 knockdown was performed to confirm functional rescue.</p><p><strong>Results: </strong>CPNE3 was upregulated in CRC. Silencing it reduced proliferation, migration, and invasion, and increased apoptosis and autophagy. Overexpression had opposite effects, increased KIF4 levels, activated PI3K/AKT/mTOR signaling, and suppressed autophagy markers (ATG5, ATG7, P62, LC3-II). CPNE3 directly interacted with KIF4. Knocking down KIF4 reversed the oncogenic effects of CPNE3 overexpression.</p><p><strong>Conclusions: </strong>CPNE3 promotes CRC progression by interacting with KIF4 and regulating PI3K/AKT/mTOR and autophagy pathways. The CPNE3-KIF4 axis is a potential therapeutic target.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 1","pages":"17"},"PeriodicalIF":2.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147433270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Private equity acquisitions of hospitals and the changing landscape of care for patients with gastrointestinal cancer.","authors":"Eshetu Worku, Zayed Rashid, Mujtaba Khalil, Selamawit Woldesenbet, Timothy M Pawlik","doi":"10.21037/jgo-2025-702","DOIUrl":"https://doi.org/10.21037/jgo-2025-702","url":null,"abstract":"<p><strong>Background: </strong>The growing presence of private equity (PE) in the United States (U.S.) healthcare raises concern about access, costs, care quality, and outcomes. This study explores the specific impact of PE-owned hospitals on gastrointestinal (GI) cancer care.</p><p><strong>Methods: </strong>Patients undergoing GI cancer surgery were identified from the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database (2012-2020). Propensity score matching compared PE and non-PE hospitals. Difference-in-difference and multivariable models evaluated GI surgical outcomes, adjusting for patient and hospital-level characteristics.</p><p><strong>Results: </strong>Among 1,887 GI cancer patients (hepatopancreatic: n=127, 6.7%; colorectal: n=1,760, 93.3%), the majority were male (n=1,030, 54.6%), White (n=1,526, 80.9%), with early-stage disease (stage I/II: n=1,009, 54%) and a median age of 75 [interquartile range (IQR), 70-82] years. Surgeries at PE-owned hospitals comprised 31.7% (n=599). Compared to non-PE hospitals, patients treated at PE-owned centers were more often Black (18.7% <i>vs.</i> 12.1%), socioeconomically vulnerable (48.4% <i>vs.</i> 36.1%), and had early-stage cancer (57.1% <i>vs.</i> 52.5%) (P<0.05). PE ownership correlated with reduced clinical staffing (physicians: -19; nurses: -43), fewer Medicaid patients (-194), and lower surgical costs (-$341) (all P<0.05). Hospital-acquired infections rose post-acquisition (30.4% to 43.7%, P=0.02), while non-PE hospitals maintained lower rates (11.2% to 19.6%, P<0.001). The risk of perioperative-complications [risk ratio (RR) =0.80; 95% confidence interval (CI): 0.54-1.20], hospital-acquired infections (RR =0.77; 95% CI: 0.37-1.63), and 90-day-mortality (RR =1.27; 95% CI: 0.60-2.66) were comparable at PE-acquired versus non-acquired hospitals.</p><p><strong>Conclusions: </strong>PE hospital acquisitions reduce staffing, limit Medicaid patient's access, and increase infection risks-underlining the need to protect equity and quality in GI cancer care.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 1","pages":"4"},"PeriodicalIF":2.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147433288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and validation of an explainable machine learning model for early postoperative pulmonary complications after esophagectomy in patients with esophageal cancer.","authors":"Feifei Liu, Zhibo Wang","doi":"10.21037/jgo-2025-aw-889","DOIUrl":"https://doi.org/10.21037/jgo-2025-aw-889","url":null,"abstract":"<p><strong>Background: </strong>Postoperative pulmonary complications (PPCs) constitute a major adverse outcome following esophagectomy for esophageal cancer (EC). This study aimed to develop and validate an interpretable machine learning (ML) model for early prediction of PPCs within 30 days post-esophagectomy.</p><p><strong>Methods: </strong>A retrospective cohort of 975 patients undergoing esophagectomy was enrolled and divided into training and internal testing sets in a 7:3 ratio. An independent prospective cohort of 417 participants served as the external validation cohort. Feature selection was performed using the least absolute shrinkage and selection operator (LASSO) and Boruta algorithms to identify key predictors. Eight ML models were subsequently constructed using the selected features. Model performance was assessed through the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, F1-score, calibration curves, and decision curve analysis (DCA). SHapley Additive exPlanations (SHAP) method was employed to interpret the ML models.</p><p><strong>Results: </strong>Among the retrospective cohort, the incidence of PPCs was 43.2% (421/975). Feature selection identified seven independent predictors of PPCs. Among the ML models evaluated, category boosting (CatBoost) demonstrated superior performance, achieving an AUC of 0.890 [95% confidence interval (CI): 0.853-0.928] in internal testing cohort and 0.888 (95% CI: 0.856-0.920) in external validation. Calibration curves indicated strong agreement between predicted and observed outcomes, while DCA confirmed clinical utility. SHAP analysis revealed surgical duration, neoadjuvant therapy, and advanced age as the three most influential predictors of PPCs.</p><p><strong>Conclusions: </strong>The CatBoost-based model exhibited robust predictive accuracy for early PPCs following esophagectomy, achieving an AUC of 0.888 in external validation. Integration of SHAP analysis enhanced interpretability, offering actionable insights for risk stratification and guiding perioperative clinical-making. This tool may facilitate timely interventions to mitigate postoperative morbidity in EC patients.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 1","pages":"3"},"PeriodicalIF":2.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972038/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147433319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case report: Masson's tumor (intravascular papillary endothelial hyperplasia) of the abdominal cavity.","authors":"Yiran Ren, Xiangrong Yu","doi":"10.21037/jgo-2025-635","DOIUrl":"https://doi.org/10.21037/jgo-2025-635","url":null,"abstract":"<p><strong>Background: </strong>Masson's tumor, also known as intravascular papillary endothelial hyperplasia (IPEH), is a rare benign vascular lesion that can arise in a wide range of anatomical sites, most frequently within the dermis and subcutaneous tissues. Because its clinical manifestations and radiological appearances are nonspecific and may closely mimic those of malignant vascular neoplasms or soft-tissue sarcomas, it is frequently misinterpreted as a malignant tumor, particularly in the preoperative setting. To draw attention to this important diagnostic pitfall, we present a case of IPEH that was initially misdiagnosed as a malignant lesion, with the aim of improving recognition of its characteristic features and thereby enhancing diagnostic accuracy and reducing the likelihood of future misdiagnosis.</p><p><strong>Case description: </strong>A 52-year-old woman was incidentally found to have a well-circumscribed, hypervascular intra-abdominal mass during a chest computed tomography (CT) scan. Magnetic resonance imaging showed a T1-hypointense/T2-hyperintense lesion with restricted diffusion and progressive enhancement. Given its marked hypervascularity and intra-abdominal location, a neoplastic process was initially suspected. However, following surgical exploration with complete excision of the mass and histopathological evaluation, the lesion was ultimately diagnosed as IPEH.</p><p><strong>Conclusions: </strong>Intra-abdominal Masson's tumor is exceedingly rare, and its imaging characteristics have not been systematically defined. In this report, we describe a surgically confirmed case of intra-abdominal Masson's tumor and place particular emphasis on its radiological features, including a well-circumscribed hyper vascular mass with progressive enhancement but without overt signs of malignancy. Despite these suggestive imaging findings, the definitive diagnosis continues to depend on histopathological assessment combined with immunohistochemical staining. By presenting this case, we hope to raise awareness of this benign yet deceptive vascular lesion and highlight that a pattern of progressive enhancement in the absence of malignant imaging features may prompt consideration of Masson's tumor in the differential diagnosis, thereby facilitating earlier and more accurate diagnosis.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 1","pages":"33"},"PeriodicalIF":2.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147432464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anlotinib and penpulimab in advanced hepatocellular carcinoma: a new contender emerges.","authors":"Oluseyi Abidoye, Daniel Ahn","doi":"10.21037/jgo-2025-aw-868","DOIUrl":"https://doi.org/10.21037/jgo-2025-aw-868","url":null,"abstract":"","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 1","pages":"38"},"PeriodicalIF":2.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147432992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Checkpoint inhibition in advanced biliary tract cancer: progress, limitations, and the search for biomarker-driven strategies.","authors":"Elisa Giovannetti, Mafalda Angelica Rocco, Virginia Agnetti, Laiba Mariyam, Teresa Maria Assunta Fasciana, Ingrid Garajová","doi":"10.21037/jgo-2025-aw-837","DOIUrl":"https://doi.org/10.21037/jgo-2025-aw-837","url":null,"abstract":"","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 1","pages":"35"},"PeriodicalIF":2.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147433227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ΔSII-based nomogram for prognosis prediction after radical resection for hepatocellular carcinoma.","authors":"Yang Zou, Min Jin, Ming Luo, Kai He","doi":"10.21037/jgo-2025-772","DOIUrl":"https://doi.org/10.21037/jgo-2025-772","url":null,"abstract":"<p><strong>Background: </strong>Primary liver cancer (PLC) ranks sixth in global incidence and third in cancer mortality. Chronic inflammation drives hepatocarcinogenesis via fibrosis. Despite curative resection, hepatocellular carcinoma (HCC) patients have high recurrence rates (50% at 3 years and 70% at 5 years). In addition to pathological factors [e.g., an alpha-fetoprotein (AFP) concentration >400 ng/L and vascular invasion], systemic immune inflammation influences the prognosis. The systemic immune-inflammation index (SII) has prognostic value, but the preoperative SII does not account for surgical impact. We propose a novel postoperative/preoperative SII ratio (ΔSII) to predict survival and recurrence, integrated into a ΔSII-based prognostic nomogram.</p><p><strong>Methods: </strong>We retrospectively analyzed 244 HCC patients undergoing radical resection, randomly divided into training (n=171) and validation (n=73) cohorts at a 7:3 ratio. The optimal ΔSII cutoff for overall survival (OS) was determined by receiver operating characteristic (ROC) curve analysis. Clinicopathologic associations were assessed with Chi-squared/Fisher tests. Variable selection involved univariable Cox, least absolute shrinkage and selection operator (LASSO), and Boruta algorithms; multivariable Cox models were used to construct OS/recurrence-free survival (RFS) nomograms. Performance was evaluated via time-dependent area under the curve (AUC), calibration curves, and decision curve analysis (DCA).</p><p><strong>Results: </strong>The ΔSII outperformed preoperative SII in predicting OS (AUC: 0.770 <i>vs.</i> 0.593, P<0.001). High-ΔSII patients (n=59) had higher rates of multifocal tumors (20.3% <i>vs.</i> 6.3%, P=0.005), major resections (42.4% <i>vs.</i> 17.0%, P<0.001), and transfusions (18.6% <i>vs.</i> 9.8%, P=0.04) compared to low-ΔSII patients (n=112). Survival was superior in the low-ΔSII group, with median OS 58 <i>vs.</i> 23 months [hazard ratio (HR) =3.71, P<0.001] and median RFS 39 <i>vs.</i> 16 months (HR =2.81, P<0.001). Multivariable analysis confirmed high ΔSII (HR =3.71), AFP ≥400 ng/mL (HR =1.79), and major resection (HR =2.45) as independent risk factors for OS; hepatitis B virus (HBV) positivity (HR =2.03) was an additional risk factor for RFS. The nomogram showed AUCs of 0.776/0.894 (1-year OS) and 0.848/0.653 (1-/3-year RFS), with good calibration (Brier score 0.11-0.19) and clinical utility.</p><p><strong>Conclusions: </strong>The ΔSII-based nomogram effectively predicts OS/RFS after resection, enabling individualized management for high-risk HCC patients.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 1","pages":"22"},"PeriodicalIF":2.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147433244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In search of the best perioperative treatment for gastroesophageal cancer: is there a role for antiangiogenesis?","authors":"Thierry Alcindor","doi":"10.21037/jgo-2025-779","DOIUrl":"https://doi.org/10.21037/jgo-2025-779","url":null,"abstract":"","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 1","pages":"37"},"PeriodicalIF":2.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147433246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}